9.92

0.10% 0.010

After Hours: 9.92

Dynavax Technologies Corp (DVAX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Dynavax Technologies Corp stock is traded at $9.92, with a volume of 1.45M. It is up +0.10% in the last 24 hours and up +1.33% over the past month. Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Previous Close:

$9.91

Open:

$9.89

24h Volume:

1.45M

Relative Volume:

0.65

Market Cap:

$1.25B

Revenue:

$260.81M

Net Income/Loss:

$20.48M

P/E Ratio:

76.31

EPS:

0.13

Net Cash Flow:

$22.67M

1W Performance:

+1.54%

1M Performance:

+1.33%

6M Performance:

-22.32%

1Y Performance:

-11.67%

1-Day Range:

$9.8136

$10.13

1-Week Range:

$9.73

$10.13

52-Week Range:

$9.22

$14.63

Dynavax Technologies Corp Stock (DVAX) Company Profile

Name

Dynavax Technologies Corp

Sector

Healthcare (1173)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

(510) 848-5100

Address

2100 POWELL STREET, EMERYVILLE, CA

Employee

405

Twitter

@DynavaxCorp

Next Earnings Date

2024-11-07

Latest SEC Filings

DVAX's Discussions on Twitter

Compare DVAX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DVAX Dynavax Technologies Corp	9.92	1.25B	260.81M	20.48M	22.67M	0.13
RGC Regencell Bioscience Holdings Ltd	17.04	303.95B	0	-5.87M	-767.30K	-0.45
ZTS Zoetis Inc	155.95	74.39B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.37	48.97B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	15.46	47.39B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	16.76	20.17B	16.54B	-1.64B	749.00M	-1.45

Dynavax Technologies Corp Stock (DVAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-11-25	Downgrade	Goldman	Neutral → Sell
Feb-01-24	Initiated	Goldman	Neutral
Sep-27-22	Initiated	JMP Securities	Mkt Outperform
Jan-06-22	Resumed	Goldman	Buy
Aug-06-21	Initiated	Goldman	Buy
Aug-07-20	Reiterated	H.C. Wainwright	Buy
Aug-03-20	Reiterated	H.C. Wainwright	Buy
Jun-15-20	Initiated	Evercore ISI	Outperform
Oct-18-19	Initiated	H.C. Wainwright	Buy
Jul-11-19	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Feb-27-19	Reiterated	Cantor Fitzgerald	Overweight
May-10-18	Upgrade	JP Morgan	Neutral → Overweight
Mar-08-18	Reiterated	Cantor Fitzgerald	Overweight
Feb-14-18	Downgrade	JP Morgan	Overweight → Neutral
Sep-25-17	Reiterated	RBC Capital Mkts	Outperform
Sep-15-17	Initiated	Cantor Fitzgerald	Overweight
Jul-31-17	Upgrade	JP Morgan	Neutral → Overweight
Jul-31-17	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
May-09-17	Reiterated	RBC Capital Mkts	Sector Perform
Apr-28-16	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Apr-27-16	Downgrade	JP Morgan	Overweight → Neutral
Nov-30-15	Initiated	RBC Capital Mkts	Outperform
Nov-25-13	Upgrade	MLV & Co	Hold → Buy
Feb-25-13	Downgrade	MLV & Co	Buy → Hold
Nov-16-12	Reiterated	MLV & Co	Buy

View All

Dynavax Technologies Corp Stock (DVAX) Latest News

Jun 18, 2025